Related Experiment Video
Updated: May 16, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
Meghan E Turnis1, Alan J Korman, Charles G Drake
1Department of Immunology; St. Jude Children`s Research Hospital; Memphis, TN USA.
Oncoimmunology
|November 22, 2012
Summary
Dual blockade of PD-1 and LAG-3 in cancer immunotherapy synergistically enhances tumor clearance. This study explores future combinatorial approaches for more effective cancer treatments.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Cancer immunotherapy aims to activate the immune system against tumors.
- Immune checkpoint inhibitors like PD-1 and LAG-3 are key therapeutic targets.
- Previous research suggests potential benefits of targeting multiple immune checkpoints.
Purpose of the Study:
- To evaluate the synergistic effect of dual PD-1 and LAG-3 blockade on tumor clearance.
- To discuss the implications of these findings for future combination immunotherapies.
Main Methods:
- Therapeutic blockade of both PD-1 and LAG-3 pathways in a preclinical cancer model.
- Assessment of tumor clearance and immune response.
Main Results:
- Demonstrated a synergistic enhancement in tumor clearance with dual PD-1 and LAG-3 blockade.
- Identified a robust anticancer immune response.
Conclusions:
- Dual PD-1 and LAG-3 blockade represents a promising strategy for enhancing cancer immunotherapy.
- Findings support the development of combinatorial immunotherapeutic approaches for improved patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...